V. 5 Uncertainties and ethics
Trust is built on honesty. This appendix speaks openly about the limits of the treatment and of this book, about the ethical principles and the regulatory background – not to unsettle you, but to enable you to make well-founded, informed decisions together with your treating physician.
The strength of the evidence and its limits
The evidence for treating recurrent Clostridioides difficile[G] infection with FMT[G] is strong. Faecal microbiota transplantation is the recommended therapy for multiple recurrence[G] in the international guidelines (IDSA/SHEA: McDonald 2018 [023]; Johnson 2021 [028]), and since the classic randomised trial (van Nood, 2013 [029]) further clinical trials and guideline syntheses have confirmed the high cure rate compared with antibiotics (AGA 2024 [447]; BSG/HIS 2024 [777]). The capsule-based, orally administered form has proved equivalent in efficacy to colonoscopic delivery (Kao, 2017 [008]).
At the same time, we must say honestly: the long-term data are limited. FMT is a relatively young treatment method, and little data are available on follow-up over many years or many decades (Saha, 2021 [087]; Yau, 2024 [088]). Science is still actively researching the relationship between the gut flora, the immune system, and long-term health. This is not a reason for concern in the established indication (recurrent CDI), but it is a reason for the treatment always to be carried out consciously and under medical supervision.
The limits of the SIS and of decision support
The SIS (Symptom Importance Scale) featured in the book is an internal, decision-support tool that helps with the objective assessment of the severity of CDI and the selection of the appropriate preparation. It is important to know, however, that the SIS has not yet been prospectively validated – that is, the reliability of the scoring system has not yet been fully confirmed by forward-looking clinical studies. The SIS therefore never replaces the medical decision: it solely supports the treating physician's professional judgement, and is not suitable for automatic classification without medical review. The scale is currently valid only for adults and exclusively for C. difficile infection.
Regulatory status
The regulatory background of the DiffBiome service is as follows. The activity takes place within the framework of "Medical Laboratory Services (869015)", and the preparations fall into the category of substances of human origin (SoHO[G] – Substances of Human Origin). The finalisation of the European Union classification is expected, as planned, towards the end of 2027. The treatment is in all cases tied to medical supervision. From a legal standpoint, MicroBiome Bank does not provide a product but a service; the contents of the capsule are the property of the donor until the recipient[G] pays. Adverse events[G] must be reported within the framework of pharmacovigilance to the competent authorities (EMA/FDA/local authority).
Donor ethics and informed consent
FMT is based on the gift of another person – the donor[G]. This carries a particular ethical responsibility on both sides. Donors are volunteers who undergo strict, multi-stage screening (twofold serological testing, multiplex PCR pathogen panel, exclusionary medical and lifestyle criteria), and who take part in the programme informed and with their consent given. On the recipient's side, informed consent is likewise the foundation: you have the right to understand what you are receiving, why, and with what risks, and you have the right to ask questions before you start. This book serves precisely that informedness.
What this book does not replace
Finally, the most important point: this book is an educational publication that supports self-management; it does not replace medical diagnosis, treatment, or personal medical advice. What it contains provides general information, but your situation is unique. Every treatment decision – starting the course, the dose, tapering, a repeat cycle – must be made together with your treating physician. If you notice a warning sign (red flag), do not read the book – turn to a doctor immediately. The book is your companion on the journey; your doctor is your guide.
References
[008] Kao D, Roach B, Silva M et al. Effect of Oral Capsule– vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium. difficile Infection: A Randomized Clinical Trial. JAMA. 2017. Link
Noninferiority randomized trial in 116 adults with recurrent CDI across three Canadian academic centres comparing oral capsule FMT with colonoscopy-delivered FMT (enrolment 2014–2016; noninferiority margin 15%). The study tested whether less invasive capsule delivery matches colonoscopy in preventing further CDI recurrence. Results support clinical equivalence between routes, enabling broader and lower-burden access to FMT for recurrent CDI.
[023] McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC et al. Clinical Practice Guidelines for Clostridium. difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases. 2018. Link
Comprehensive IDSA/SHEA clinical practice guideline on the diagnosis, treatment and prevention of C. difficile infection in adults and children. It defines severity categories (non-severe, severe, fulminant) and characterises fulminant disease by hypotension or shock, ileus or toxic megacolon — findings that require inpatient care, intravenous therapy and surgical consultation. For multiply recurrent infection in which antibiotic therapy has repeatedly failed, faecal microbiota transplantation is recommended. This document provides the international frame to which the book's red flags and hospital-referral signs are aligned.
[028] Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clinical Infectious Diseases. 2021. Link
A focused update of the 2017 IDSA/SHEA guideline, limited to treatment recommendations. The principal change is that fidaxomicin is now preferred over vancomycin for an initial episode — a conditional recommendation with moderate certainty — because although initial cure is similar, sustained cure is better. For recurrent episodes fidaxomicin is likewise preferred, as is a tapered and pulsed vancomycin regimen. Bezlotoxumab is offered as an adjunct for patients at high risk of recurrence. The guideline states explicitly that vancomycin remains an acceptable choice where fidaxomicin is unavailable, and metronidazole has receded even for mild disease. For the SIS the guideline matters because it confirms that the treatment decision depends not only on current severity but on the risk of recurrence — the duality that underlies the acute and prognostic subscores of the SIS.
[029] van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent Clostridium. difficile. The New England Journal of Medicine. 2013. Link
The first randomised controlled trial comparing faecal microbiota transplantation with standard antibiotic therapy in recurrent *Clostridioides difficile* infection. Patients were assigned to three arms: donor faeces given through a duodenal tube after a short course of vancomycin, vancomycin alone, or vancomycin with bowel lavage. The trial was stopped early because the difference was so large: in the transplantation arm 81 percent of patients were cured after the first infusion and 94 percent including repeat infusions, against 31 and 23 percent in the two vancomycin arms. After treatment the diversity of the patients' faecal flora came to resemble that of the donors. This paper turned microbiota transplantation into an evidence-based treatment and is the starting point for the dosing regimen of the present protocol.
[087] Saha S, Mara K, Pardi D, Khanna S. Long-term Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Gastroenterology. 2021. Link
Long-term safety of FMT in rCDI: low infection transmission risk; new diagnoses likely unrelated to FMT — Mayo Clinic 609 patients, 6.8-year prospective data — 609 patients, median 3.7 years follow-up (range 2.0–6.8 years). At 1 year: 9.5% reported a new CDI episode. Long-term, 73 new diagnoses (13% GI, 10% weight gain, 11.8% infection) — all judged unrelated to FMT. Higher diarrhea risk in IBD, dialysis-dependent kidney disease, and patients undergoing repeated FMT.
[088] Yau Y, Lau L, Lui R, Wong S, Guo C, Mak J, Ching J, Ip M, Kamm M, Rubin D, Chan P, Chan F, Ng S. Long-Term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data Over 8 Years From the Hong Kong FMT Registry. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2024. Link
Excellent long-term safety profile of FMT based on 8-year registry data: low risk of new disease beyond 12 months; survival of CDI-treated patients significantly better than antibiotic controls — 123 patients, 510 FMTs, median 30.3 months follow-up (max 57.9 months = ~5 years). Beyond 12 months, 21 new diseases in 16 patients — all judged unrelated to FMT. No development of IBD, IBS, allergy, T2DM, or psychiatric disorder. Cumulative survival probability of FMT-treated rCDI patients significantly better than matched antibiotic controls.
[447] Peery AF, Kelly CR, Kao D et al. AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases. Gastroenterology. 2024. Link
AGA clinical practice guideline using the GRADE framework to address fecal microbiota-based therapies (conventional FMT, fecal microbiota live-jslm, fecal microbiota spores live-brpk) in adults with recurrent or severe-to-fulminant Clostridioides difficile infection, IBD/pouchitis, and IBS. The panel issued 7 recommendations. In immunocompetent adults with recurrent CDI, the AGA suggests selective use of fecal microbiota-based therapies after standard-of-care antibiotics to prevent further recurrence. Provides framework guidance integrating FDA-approved products with conventional FMT.
[777] Mullish BH, Merrick B, Quraishi MN et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut. 2024. Link
The 2024 second edition of the joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines on faecal microbiota transplant (FMT) for recurrent or refractory Clostridioides difficile infection and other potential indications. It updates the 2018 first edition with evidence from national FMT registries. It also sets out the UK regulatory framework: the MHRA treats FMT as a medicinal product for human use, centres processing and distributing FMT must obtain MHRA licences, and a pharmacy exemption may apply when FMT is supplied on a named-patient basis within a single organisation. Detailed recommendations cover donor screening, product manufacture, delivery routes and patient follow-up.